Deep Learning in the Detection and Prediction of Hydroxychloroquine Maculopathy

Recruiting now

Conditions studied: Hidroxicloroquine Intake

In brief

Hydroxychloroquine retinal toxicity affects a significant number of patients using this medication. Detection of toxicity is difficult in the early stages of the disease and depends on the subjectivity of the clinician who reads the tests (optical coherence tomography, autofluorescence and visual fields). Automating the reading of these diagnostic exams could lead to earlier detection of this pathology and reduce the burden associated with interpreting these exams in the ophthalmology service. The images that are usually taken in the screening and monitoring of hydroxychloroquine toxicity by will be collected - photography of the ocular fundus and optical coherence tomography with autofluorescence.

Key facts

Study ID

NCT06839443

Run by

Centro Hospitalar de Lisboa Central

People needed

100

Starts

2024-08-01

Expected to finish

2025-06-20

Last updated by the study team

2025-02-21

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with > 10 years of HCQ intake

You may not qualify if…

• Patients with ocular diseases that might mimic HCQ maculopathy or interfer with HCQ maculopathy screening

Where it is running

• Local de Saúde São José — Portugal, Portugal (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.